Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within two years of patients stopping their treatment.
According to a study published in the BMJ, data from 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss drugs showed that they regained about one pound on average after stopping the drugs.
The same study said they were projected to return to their pre-treatment weight in about two years.
But weight was not the only thing that was projected to return after stopping the treatment. According to the same study, health risk factors like blood pressure and cholesterol levels, which saw benefits while taking the drugs, were projected to return to their old levels within 1.4 years.
GLP-1 medications tested as well
About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound. According to the study, the weight regain rate was faster for these drugs, with an average of 1.8 pounds per month.
“But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters.
Weight loss drugs have shown some success
Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years. Back in October 2025, a survey from the Gallup National Health and Well-Being Index showed that there were an estimated 7.6 million fewer obese people in the United States compared to 2022.
In 2022, the U.S. adult obesity rate was a record-high 39.9%, while in 2025, that rate gradually declined to 37%. While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study.
Contributing: Nicole Fallert, USA TODAY; Reuters
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at [email protected] and follow him on X @fern_cerv_.
This article originally appeared on USA TODAY: Here's how fast you can gain weight after ending GLP-1, per study
latest_posts
- 1
Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging. - 2Falcon 9 rocket launches Starlink satellites before making 550th SpaceX landing (video)
- 31st human missions to Mars should hunt for signs of life, report says
- 4Rights group: At least 2,500 deaths during protest crackdown in Iran
- 5Tech Patterns: Contraptions That Will Shape What's in store
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
- Science is best communicated through identity and culture – how researchers are ensuring STEM serves their communities
- Humpback whale stranded on Germany's Baltic coast frees itself
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Cheetos and Doritos to launch new versions without artificial dyes
- Cognizant Couture d: A Survey of \Moral Decisions and Sharp Looks\ Maintainable Style
- Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
